Harvard Medical School

Third Rock launches MyoKardia with $38M for genetic heart disease

Friday, September 21, 2012 10:51 AM

Third Rock Ventures, a venture capital firm of Boston, Mass., has formed new company MyoKardia with a $38 million Series A financing. MyoKardia is developing a pipeline of novel small molecule therapeutics that address key clinical needs for patients with genetic heart disease.

More... »

Galenea receives $3M to develop translational EEG biomarkers for schizophrenia

Friday, September 7, 2012 12:22 PM

Researchers at Galenea, based in Cambridge, Mass., and collaborator Dr. Kevin Spencer of the VA Boston Healthcare System and Harvard Medical School, have been awarded a five-year, $3 million grant from the National Institute of Mental Health (NIMH).

More... »

Thirty teams compete to interpret three families' genomes

Monday, August 20, 2012 12:08 PM

In a contest led by Boston Children's Hospital, 30 teams from around the world are vying to interpret the DNA sequences of three children with rare conditions whose cause remains a mystery—with the goal of establishing "best practices" for interpreting genomic data.

More... »

Oracle Institute and Oracle Labs announce research projects

Friday, February 3, 2012 01:27 PM

Oracle Health Sciences Institute, in partnership with Oracle Labs, has announced its first group of research projects, which includes initiatives with Brigham and Women’s Hospital and Harvard Medical School, the Coalition Against Major Diseases (CAMD) at the Critical Path Institute and the Human-Computer Interaction Lab (HCIL) at the University of Maryland.

More... »

Giant leap for HIV cure

Wednesday, January 11, 2012 11:09 AM

After 30 years of unsuccessful attempts, an HIV vaccine may be within reach. That’s what scientists at Crucell NV of the Netherlands (a subsidiary of Johnson & Johnson) are saying.

More... »

Researchers use RNA technology to block inflammation

Tuesday, October 11, 2011 01:26 PM

Massachusetts General Hospital (MGH) researchers - along with collaborators from Massachusetts Institute of Technology (MIT) and Alnylam Pharmaceuticals - have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication in Nature Biotechnology, the investigators describe using small interfering RNA technology to silence the biochemical signals that attract a particular group of inflammatory cells to areas of tissue damage.

More... »

Enzon to cut half of its workforce in 2012

Friday, September 23, 2011 01:14 PM

Enzon Pharmaceuticals, a biotechnology company, said it will cut almost half its workforce in June 2012 to reduce annual operating costs by about $6 million, according to Bloomberg.

More... »

Harvard disciplines three psychiatrists under Sunshine Act

Wednesday, July 6, 2011 09:59 AM

Harvard Medical School and Massachusetts General Hospital have disciplined three faculty members in a conflict-of-interest case that became a prime exhibit in the debate over the federal Physician Payments Sunshine Act of 2010, according to the NPR Health Blog.

More... »

Dr. Ashley I. Bush joins Adeona's scientific advisory board

Friday, April 1, 2011 11:16 AM

ANN ARBOR, Mich.-based Adeona Pharmaceuticals, a developer of medicines for serious central nervous system diseases, announced that Ashley I. Bush, M.D., Ph.D., has joined the company's scientific advisory board.

More... »